Pain in the Adult Flashcards

1
Q

Definition of Pain

A
Pain is an unpleasant sensory and 
emotional experience associated 
with actual or potential tissue 
damage or described in such terms.
Pain is whatever the person 
experiencing it says that it is; 
existing whenever s/he says that 
it does.

MARGO MCCAFFREY, 1969

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Barriers to pain management

A

Only about 49% of patients with pain
achieve satisfactory control

Patients, healthcare providers, and the
healthcare system present barriers to
optimum pain control

Fear of addiction and dependence

Patients may be reluctant to report pain

Scales for measuring pain intensity are not
used correctly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Categorization of pain- important

A

Somatic- superficial of deep

Superficial-skin- prickly, sharp, burning

Deep- aching, throbbing, (joints, bones,
muscle, skin or connective tissue)

Visceral- internal organs, linings of body
cavities, thorax and abdomen.

Visceral nociceptors respond to
inflammation, stretching, and ischemia-
intense cramping

Examples of Nociceptive pain-

Surgical incisions

Broken bones, arthritis,

Pancreatitis, inflammatory bowel disease

Treatment-usually respond to NSAIDS,
opiods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Nociceptors

A

Specialized nerve endings that respond to threshold
stimulation by thermal, mechanical, or chemical stimuli.

Nociceptor activation causes opening of cation and Na
channels ? opening of voltage gated Na channels ?
action potentials (intensity depends on duration and
frequency of nociceptor stimuli) that are transmitted via

Ab- fast transmission?touch,vibration, rarely pain

Ad- fast transmission, pricking pain

C- slower transmission, slow burning pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nociception

A

Transduction

Conversion of
thermal, chemical,
mechanical stimulus 
to electrical activity at 
nociceptor

Na channels

Conduction

Passage of action
potential along the 
first order neuron to 
dorsal horn of spinal 
cord

Nociception

Transmission

Transfer and modulation of
input from one neuron to
another

Substance P, Glutamate, Brain
derived neurotropic factor

Inhibitory interneurons

Perception

Awareness and meaning of pain

Modulation

Descending pathways inhibit
transmission of nociceptive
impulses

Endogenous opioids,
norepinephrine, serotonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Neural Plasticity

A

Neurobiological process by which changes in the
nervous system can alter the response to stimuli

Modulation

Reversible change in the excitability of neurons

Modification

Long lasting change in expression of neurotransmitters,
receptors, ion channels; and structure and functionality of
neurons ? modification and distortion of the usual stimulus
response ? abnormal responses such as hyperalgesia and
allodynia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Peripheral Sensitization

A

Excitability threshold of nociceptors is lowered

Most important mediators are those of
inflammation

Bradykinin, serotonin, histamine, prostaglandin,
leukotrines, cytokines, nitric acid, protons, neurotropic
growth factors

Results in increased capacity of tactile, low level
stimuli to generate hyperexcitability of nociceptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Central Sensitization

A

Increases responsiveness of dorsal horn neurons to
stimuli ? heightened excitability and sensitivity
extending beyond site of injury

Loss of modulating and inhibitory signals ?
exaggerated response to noxious stimuli

NMDA receptor activation is a main factor

Pain is not static

Active process involving peripheral and central
nervous system

Neural plasticity shifts threshold and
responsiveness to pain over time, so that

Pain may appear to occur spontaneously, in an
exaggerated or prolonged course, or in response to
innocuous stimuli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PAIN ASSMT:

A

P lace: Where?

A mount: How much?

I ntensifiers: Worse?

N ullifiers: Better?

E ffects: Medication effect/side effect? Effect on
QOL?

D escription: How does it feel?
+
Pain History

prior therapies, recent analgesic use

Medical History

Diagnosis, prognosis, other health problems

Psychosocial History

Physical Exam

Diagnostic test results if appropriate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical Examples of Pain

Syndromes

A

Nociceptive

Surgery, trauma

Inflammatory

Bone metastases, arthritis, healing incision

Neuropathic

PHN, diabetic neuropathy, nerve root compression

Functional

IBS, Fibromyalgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rational Approach to Pain

Management

A

T reat treatable causes

O ptimize analgesic
medications

N on pharmacological
modalities

I nvasive procedures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment of Pain

A

Whenever possible- oral preparations

The underlying cause of pain should be diagnosed

Ask about pain regularly, assess quality duration, location

Ask about goals for pain control and management preferences

Choose options appropriate for patient, family, and setting-
dosage, route, drug type, cost.

Frequent follow up

May need pain contract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Acetaminophen

A

Analgesic for mild-to-moderate pain

Ceiling dose: 1000 mg/dose

Maximum dose 2000-4000 mg/day

FDA maximum dose is still 4000 mg/day

McNeil lowered recommended maximum dose to 3000
mg/day

Lower dose in older adults and individuals with hepatic
impairment

Concerns regarding multiple OTC products containing
acetaminophen; use with alcohol

Liver toxicity if maximum dose exceeded

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Tramadol (Ultram)

A

Opioid receptor agonist with inhibition of re-uptake of
serotonin and norepinephrine

Ceiling dose 300-400 mg/24 hours

Usual dose 50-100 mg q 6h PRN

Side effects: dizziness, constipation, sedation, nausea

Reduces seizure threshold

Combination with other opioids controversial

Studies show effectiveness in treatment of peripheral
neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

INITIATING OPIOIDS IN THE

TREATMENT OF CNCP

A

When Acetaminophen, NSAIDs, and topical agents are no
longer effective

Patients have multiple co-morbidities, and not candidates for
corticosteriod injections

Neuropathic pain guidelines recommend tx with TCA, and
SSRI, gabapentin, lyrica

May be considered in moderate to severe pain impacting
quality of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Opioid Risk Evaluation

A

Assess risk- integral part of prescribing

Check validated risk evaluation tools

Opioid risk tool

Diagnosis, risk, itractability, risk, Efficacy score

Opioid assessment for Patients with Pain-Revised (SOAPP-R)
can aid in assessing risk of addiction

Pain contract

Urine drug testing- strongly recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Incomplete Cross Tolerance

A

A patient who is tolerant to the effect and
side effects of one opioid may not be
equally tolerant to the effects and side
effects of another opioid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Converting to new opioid

A

Decrease equi-analgesic dose by 1/3 to 1/2
because of incomplete cross tolerance

90 mg oral morphine ? 30 mg = 60 mg oral
morphine/24 hours

New dose: 30 mg SR Morphine q12h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Opioid for Breakthrough* Pain

A

Determining the ?as-needed? dose:

Each ?as needed? dose should equal 10%-20% of the 24-hour dose
of background opioid

20
Q

Opioid Selection

A

Patient preference and experience

Availability of appropriate dosing forms
and routes of administration

Drug pharmacokinetics

Cost and insurance coverage

21
Q

Pharmacokinetic Considerations

A

Morphine is the standard opioid

Active metabolite

Hydromorphone (Dilaudid)

Active metabolite

Methadone

Long and variable half life necessitates careful
monitoring for sedation

Fentanyl

Liphophillic

Codeine

Analgesic ceiling effect

22
Q

Transdermal Fentanyl

A

For stable, chronic pain

12-24 hours for onset and
discontinuation of action

Heat increases absorption

Hydration and nutritional status may
affect absorption

23
Q

Methadone

A

Theorized action as NMDA receptor antagonist
makes it useful in neuropathic pain

Long and variable half life can lead to accumulation
of drug and sedation

In high dose, may cause Q-T prolongation

High dose is > 300mg/day

24
Q

Inflammatory pain such as pain from bone

metastasis often responds to:

A

NSAIDs

25
Q

Non-Steroidal Anti-inflammatory Drugs

A

Effective analgesic for somatic pain; often combined
with opioid

Examples: Ibuprofen, naproxen, aspirin, keterolac, celecoxib

Ceiling doses for each

Side effects/toxicities

Dyspepsia

GI ulceration/bleeding

PPI or misoprostol may limit incidence

Renal and hepatic damage

Inhibition of platelet function

Cardiothrombotic events

26
Q

Co-analgesics for Bone Pain

A

Calcitonin

Bisphosphonates

Pamidronate

Zoledronic acid

Radioisotopes

Samarium

Strontium

Rhenium

27
Q

Co-analgesics for Neuropathic Pain

A

Anticonvulsants

First line: Gabapentin* (Neurontin)

Second line: Trileptal, Topamax, Zonegran

Third Line: Phenytoin* (Dilantin),
Carbamazepine* (Tegretol), Valproic Acid
(Valproate)

New: Pregabalin* (Lyrica)
Corticosteroids

Anti-depressants

Tricyclics*: Amitriptyline (Elavil), Nortriptyline
(Pamelor), Despiramine

Anticholinergic side effects

Mixed action: Duloxetine* (Cymbalta),
Venalfexine* (Effexor)

Lidoderm patches*

28
Q

Topical Analgesics

A

EMLA

Lidoderm patches

Viscous Lidocaine

29
Q

Opioid Induced Constipation

A

Tolerance does not develop

Aggressively prophylactic with scheduled doses of

Stool softener

Docusate

Mild stimulant laxatives

Senna

Miralax

Lactulose

Biscodyl

Avoid bulk forming laxatives like Metamucil (phsyllium), Citrucil
(methylcellulose)

BeneFiber maybe reasonable option

30
Q

Managing Opioid Side Effects

A

P sychostimulants

persistent sedation

L axatives

constipation

A ntiemetics

nausea new drug or
increased doses

T olerance
development

Nausea, sedation,
confusion with initial or
increasing doses

O pioid Rotation

pruritis, myoclonus,
urinary retention,
persistent nausea

31
Q

Non Pharmacological

Interventions

A

Heat and cold

Massage

Physical Therapy

TENS

Distraction/Relaxation/Music
Therapy/Meditation

Acupuncture/Energy Work

32
Q

TOLERANCE

A

Expected effect of chronic opioid use

Presents as decreased duration of
analgesia

Need of more frequent dosing and/or
higher doses to maintain analgesia

33
Q

DEPENDENCE

A

Expected effect of chronic use

Not a sign of addiction

Withdrawal symptoms when opioid dose is
markedly decreased or stopped abruptly

Symptoms: increased pain, anxiety,
lacrimation, rhinorrhea, nausea, diarrhea

34
Q

ADDICTION

A

Psychological dependence on the drug

Using drug for psychic effect

Often associated with drug seeking behaviors

Drug use continues despite negative legal,
social, economic effects

35
Q

Ongoing Assessment

A

Effectiveness of intervention

pain intensity

changes in quality, location of pain

amount and type of medication used

Side effects of medication

sedation

respiratory depression

nausea

constipation

36
Q

Guideline for Naloxone Use in

Opioid Tolerant Patients

A

Consider naloxone if

Unresponsive to verbal or tactile stimuli and

Respiratory rate

37
Q

Alternative Strategy to Narcan

A

Monitor closely

Protect airway

Supplemental oxygen

Frequent verbal and tactile stimuli

Decrease opioid dose and hold other sedating
medications

38
Q

NARCAN (NALOXONE)

A

Reverses opioid induced respiratory
depression and sedation

REVERSES ANALGESIA

May precipitate acute withdrawal in opioid
tolerant patients

Give incrementally

1 cc ( 0.04 mg) q 30-60 sec

39
Q

Hyperalgesia

A

Caused by neuroexcitatory effects of high dose
opioids.

Hyperalgesia: Pain increases despite ever increasing
opioid doses.

Myoclonus

Treat with opioid rotation, benzodiazepines,
sedatives/anesthetics

If appropriate to goals of care, consider
interventional options to spare opioid use.

40
Q

INTERVENTIONAL

PROCEDURES

A

Consider when pain control is unacceptable
despite unacceptable side effects.

Opioids/ local anesthetics via spinal catheters

Nerve blocks

Neurosurgical procedures
Opioids/ local anesthetics via spinal catheters

Nerve blocks

Radiofrequency ablation for some bone lesions

Kyphoplasty for some compression fractures

Neurosurgical procedures

41
Q

Why Use Spinal Analgesia?

A

Oral morphine
300 mg/day

IV morphine
100 mg/day

Epidural morphine
10 mg/day

Intrathecal morphine
1 mg/day

42
Q

Reduce Dose =

A

Reduce Side Effects

43
Q

Contraindications for Implantable Pumps

A

Tumor encroachment of the thecal sac

Emaciation

Myelosuppression

Systemic infection

Occult infection

Sensitivities to medications or
system materials

44
Q

Patient Selection for Intraspinal

Therapy

A

Chronic pain due to cancer or therapy

Life expectancy ? 3 months

Refractory Pain

Cannot be adequately relieved or controlled despite
aggressive use of usually effective therapies (e.g.
medications, other interventions) or without excessive
or intolerable side effects/complications

Favorable response to intra-spinal opioid screening
trial

No contraindications for pump implant

45
Q

Success =

A

(Pain relief + Optimal function) ?

Unmanageable side effects